Repetitive Transcranial Magnetic Stimulation With an Anti-Inflammatory Diet for Crohn's Disease

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This interventional study enrolled 56 adults with Crohn's disease experiencing constipation and functional limitations. Participants were randomized to receive either repetitive transcranial magnetic stimulation (rTMS) five times per week plus an anti-inflammatory diet for four weeks or the anti-inflammatory diet alone for four weeks. Primary outcomes include health-related quality of life and constipation severity; a secondary outcome measures inflammatory markers such as interleukins. The study is conducted at the Faculty of Physical Therapy, Suez Canal University, Egypt, with Cairo University as the lead sponsor. The trial uses non-invasive brain stimulation alongside dietary modification to explore potential synergistic effects on disease impact and symptoms.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* (1) Patients' age was ranged between 40-60 years old, (2) Both gender 50 patients participated in this study, (3) moderately to severely active refractory CD \> 4 months after diagnosis, (4) All the patients were free from genitourinary infections, (5) Neurologically free patient, (6) Patients who were able to comprehend command and willing to participate in the study, (7) Informed consent was obtained from all patients enrolled in the trial, (8) Clinical diagnosis of Alzheimer's Disease and (9) Must be able to swallow tablets.

Exclusion Criteria:

* (1) Epilepsy or seizures, (2) Metal implants in the head, skull, or neck, (3) Implanted medical devices, (4) Severe traumatic brain injury, (5) Skull fracture, (6) brain surgery, (7) Any neurological disorders that may increase risk, (8) severe cardiovascular conditions, (9) severe psychiatric disorders, (10) skin lesions, infections, (11) significant dermatological conditions at the electrode placement sites on the scalp, (12) Insulin dependent diabetes and (13) Thyroid disease.

Where it's running

• Faculty of Physical Therapy
  Giza, Giza Governorate, Egypt Recruiting

Study contacts

• Principal investigator: Research Ethical Committee Faculty of Physical Therapy — Cairo University
• Study coordinator: Mona Amin, PHD
• Email: monaamin028@gmail.com
• Phone: 01151602624

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Iron treatment for children and young adults with Crohn’s disease and iron deficiency anemia

  This study tests how different iron treatment approaches work for kids and young adults with Crohn’s disease and iron deficiency anemia.

  Recruiting Phase 4 Weill Medical College of Cornell University · New York, New York · NCT07925450

• Autologous intestinal organoids applied to Crohn's ulcers in a first-in-human dose-escalation study

  This early-phase study tests a patient-derived intestinal organoid therapy (ATORM-C) delivered during colonoscopy to Crohn’s ulcers to see if it is safe and tolerable and to get a sense of healing.

  Recruiting Phase 1 Organoidsciences LTD. · Seoul · NCT07822087

• SL-325 in Crohn's Disease: a phase 2 test for adults with moderate to severe disease

  This phase 2 study tests SL-325 against placebo in adults with moderately to severely active Crohn's disease to see if it helps improve symptoms and disease activity.

  Recruiting Phase 2 Shattuck Labs, Inc. · Little Rock, Arkansas and 19 other locations · NCT07753850

• Advanced therapies for moderately to severely active Crohn's disease or ulcerative colitis in adults

  This study tests combinations of risankizumab with either trosunilimab or ABBV-701 in adults with moderately to severely active Crohn's disease or ulcerative colitis.

  Recruiting at 66 sites Phase 2 AbbVie · Dothan, Alabama and 65 other locations · NCT07697456

• Stop PPI in active IBD: can you safely go without acid-suppressing meds?

  This study tests whether people with inflammatory bowel disease who have been on proton pump inhibitors can stop taking them and still manage their symptoms.

  Recruiting Phase 4 University of Nottingham · Nottingham · NCT07691138

• Tabellvi for moderate to severe Crohn's disease in Chinese adults

  This real-world, single-arm study tests Tabellvi® (adalimumab) in Chinese adults with moderate to severe Crohn's disease to see how often side effects occur and whether many patients reach remission by week 26.

  Recruiting Phase 4 Chia Tai Tianqing Pharmaceutical Group Co., Ltd. · Fuyang, Anhui and 6 other locations · NCT07663526

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.